tirzepatide rhabdomyolysis | GLP-1R and GIPR ligand | Sterile Fatal Outcome Following Polysubstance Use:

Warning signs include sudden severe pain in the right upper abdomen, pain radiating to the right shoulder blade, nausea and vomiting with abdominal pain, fever or chills, jaundice, and clay-colored stools

Patients can evaluate options at their own pace

Start with your primary goal

MHRA approval requires completion of Phase 3 trials, a Marketing Authorisation Application, and a subsequent NICE technology appraisal for NHS use

Luckily, there are other ways

What Trial Participants Get Free pharmaceutical-grade retatrutide for the duration of the trial Regular medical monitoring, lab work, and health assessments Compensation for time and travel (varies by site) Access to the latest trial data and results The tradeoff: You may receive placebo instead of retatrutide (most trials are randomized)